Judson Taylor
Director Técnico/Científico/I+D en DIANTHUS THERAPEUTICS, INC. .
Cargos activos de Judson Taylor
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
DIANTHUS THERAPEUTICS, INC. | Director Técnico/Científico/I+D | 11/09/2023 | - |
Historial de carrera de Judson Taylor
Antiguos cargos conocidos de Judson Taylor.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
RADIUS HEALTH, INC. | Director Técnico/Científico/I+D | 01/08/2018 | 01/05/2022 |
SYNERGY PHARMACEUTICALS INC | Corporate Officer/Principal | 01/09/2015 | 01/08/2018 |
Formación de Judson Taylor.
Temple University (Pennsylvania) | Masters Business Admin |
The Pennsylvania State University | Undergraduate Degree |
Estadísticas
Internacional
Estados Unidos | 6 |
Operativa
Chief Tech/Sci/R&D Officer | 2 |
Masters Business Admin | 1 |
Undergraduate Degree | 1 |
Sectorial
Health Technology | 4 |
Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
DIANTHUS THERAPEUTICS, INC. | Health Technology |
Empresas privadas | 2 |
---|---|
Radius Health, Inc.
Radius Health, Inc. BiotechnologyHealth Technology Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA. | Health Technology |
Synergy Pharmaceuticals LLC
Synergy Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Synergy Pharmaceuticals LLC engages on the development and commercialization of novel gastrointestinal therapies. Its commercial product, plecanatide, is marketed under the trademark name TRULANCE, which seeks to treat adults with chronic idiopathic constipation and irritable bowel syndrome with constipation. The company was founded by Kunwar Shailubhai and is headquartered in New York, NY. | Health Technology |
- Bolsa de valores
- Insiders
- Judson Taylor
- Experiencia